RENOIR Trial - RSVpreF Vaccine Efficacy over Two Seasons
N Engl J Med
.
2024 Oct 17;391(15):1459-1460.
doi: 10.1056/NEJMc2311560.
Authors
Edward E Walsh
1
,
Gonzalo Pérez Marc
2
,
Ann R Falsey
1
,
Qin Jiang
3
,
Daniel Eiras
4
,
Michael Patton
5
,
Fernando P Polack
6
,
Conrado Llapur
7
,
Pablo A Doreski
8
,
Agnieszka M Zareba
3
,
Kumar Ilangovan
9
,
Mika Rämet
10
,
Yasushi Fukushima
11
,
Nazreen Hussen
12
,
Louis J Bont
13
,
Jose Cardona
14
,
Elliot DeHaan
4
,
Tarek Mikati
4
,
Rupal N Shah
4
,
Katherine Schneider
4
,
David Cooper
4
,
Kenneth Koury
4
,
Maria-Maddalena Lino
15
,
Annaliesa S Anderson
16
,
Kathrin U Jansen
4
,
Kena A Swanson
4
,
William C Gruber
4
,
Beate Schmoele-Thoma
17
,
Alejandra Gurtman
18
Affiliations
1
University of Rochester Medical Center, Rochester, NY.
2
Hospital Militar Central, Buenos Aires, Argentina.
3
Pfizer Vaccine Research and Development, Collegeville, PA.
4
Pfizer Vaccine Research and Development, Pearl River, NY.
5
Pfizer Vaccine Research and Development, Marlow, United Kingdom.
6
Fundación INFANT, Buenos Aires, Argentina.
7
Clínica Mayo de Urgencias Medicas Cruz Blanca, San Miguel de Tucumán, Argentina.
8
Fundación Respirar Clinical Research Unit, Buenos Aires, Argentina.
9
Pfizer Vaccine Research and Development, Raleigh, NC.
10
Tampere University, Tampere, Finland.
11
Fukuwa Clinic, Tokyo, Japan.
12
Netcare Lakeview Hospital, Benoni, South Africa.
13
University Medical Center Utrecht, Utrecht, the Netherlands.
14
Indago Research and Health Center, Hialeah, FL.
15
Pfizer Worldwide Safety, Milan, Italy.
16
Pfizer Worldwide Research, Development, and Medical, Pearl River, NY.
17
Pfizer Vaccine Research and Development, Berlin, Germany.
18
Pfizer Vaccine Research and Development, Pearl River, NY alejandra.gurtman@pfizer.com.
PMID:
39413383
DOI:
10.1056/NEJMc2311560
No abstract available
Publication types
Letter